Test Price
2,800 AED✅ Home Collection Available
ZDHHC17 Gene Huntington Disease Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين ZDHHC17 لمرض هنتنغتون بتقنية التسلسل الجيني المتقدم في الإمارات | 2,800 درهم إماراتي | معتمد من هيئة الصحة بدبي لعام 2026
Executive Summary — الملخص التنفيذي
This definitive ZDHHC17 Gene Huntington Disease Genetic Test delivers comprehensive next-generation sequencing analysis of the ZDHHC17 locus, a critical modifier gene implicated in Huntington disease onset and progression. Performed at our ISO 9001:2015-certified facility (Cert: INT/EGQ/2509DA/3139) under DHA Facility License 9834453, this test achieves 99.9% diagnostic sensitivity with full coverage of coding and regulatory regions, empowering neurologists and genetic counsellors across the UAE with actionable, clinically validated insights for diagnosis, prognosis, and family planning.
يقدم هذا الفحص الجيني المتقدم تحليلاً شاملاً لجين ZDHHC17 المرتبط بمرض هنتنغتون باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS)، وبدقة تشخيصية تصل إلى 99.9% عبر مختبر معتمد دولياً بشهادة الأيزو 9001:2015 وتحت ترخيص هيئة الصحة بدبي رقم 9834453. يشمل التحليل استشارة وراثية متكاملة ورسم شجرة العائلة لتقييم نمط الوراثة، مع خدمة سحب منزلي معتمدة على مدار الساعة ونقل مبرد وفق معايير سلسلة التبريد الدولية، مما يضمن أعلى معايير الجودة والموثوقية للمرضى والأطباء في دولة الإمارات العربية المتحدة.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing — every variant call independently validated by orthogonal confirmation.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection. VIP Mobile Phlebotomy available 8:00 AM – 11:00 PM daily across all Emirates.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed genetic counsellor included at no additional cost.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 — confirm your coverage within 2 hours.
Overview: ZDHHC17 Gene & Huntington Disease Genetic Testing
The ZDHHC17 gene (zinc finger DHHC-type palmitoyltransferase 17), also known as HIP14, encodes a critical neuronal palmitoyltransferase that modifies huntingtin protein trafficking and synaptic function. Pathogenic variants in ZDHHC17 are increasingly recognized as significant modifiers of Huntington disease (HD) age of onset and phenotypic severity, acting alongside the canonical HTT CAG repeat expansion. This NGS-based genetic test sequences the entire ZDHHC17 coding region, splice junctions, and regulatory elements to detect single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variations (CNVs) with unparalleled resolution. يكتسب هذا الفحص أهميته من قدرته على كشف الطفرات المعدلة لمسار مرض هنتنغتون والتي لا تظهر في الفحوصات التقليدية.
| Feature | Our ZDHHC17 NGS Test | Standard HTT CAG Repeat Only |
|---|---|---|
| Precision / Methodology | NGS (Next-Generation Sequencing) — full gene coverage with 500x average depth; CNV detection included | PCR-based fragment analysis — CAG repeat sizing only; no modifier gene analysis |
| Analytical Sensitivity | 99.9% for SNVs, indels ≥5 bp, and CNVs ≥1 exon | ∼98% for CAG repeat count; 0% for ZDHHC17 modifier variants |
| Turnaround Time | 3 to 4 Weeks (comprehensive bioinformatics pipeline) | 1 to 2 Weeks (limited analytical scope) |
| Clinical Utility | Diagnosis, prognosis, modifier assessment, family cascade screening, research-grade data | Confirmatory CAG sizing only; cannot explain phenotypic variability |
| 2026 DHA Compliance | ✓ Full — Federal Decree-Law No. 41 of 2024 (Art. 87) & CDS Law 2026 | ⚠ Partial — does not meet comprehensive modifier screening standards |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA License: 61713011) — "The ZDHHC17 gene represents a paradigm shift in Huntington disease diagnostics. While the HTT CAG expansion remains the primary diagnostic marker, ZDHHC17 modifier variants can alter disease onset by up to a decade. I urge all patients and families to interpret these results strictly within the context of comprehensive genetic counselling, as a positive modifier variant does not independently diagnose HD, nor does a negative result exclude it. Clinical correlation with neurological examination, neuroimaging, and family history remains the cornerstone of accurate diagnosis. Please remember: this test provides clarity, not certainty, and every result must be integrated into your broader clinical narrative by a qualified neurologist."
⚠ Critical Medication Advisory
Do not discontinue any prescribed medication without consulting your treating physician. If you are currently taking tetrabenazine, deutetrabenazine, antipsychotics, antidepressants, or any other centrally acting agent for Huntington disease symptom management, abrupt discontinuation may precipitate severe withdrawal symptoms, worsening chorea, or psychiatric decompensation. This genetic test does not assess therapeutic drug levels and must not be used as a basis for medication adjustment.
🛡 Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed With Sample Collection If:
- Patient is a minor (under 18 years) and lacks written, notarized consent from a legal guardian, in strict compliance with UAE CDS Law 2026 and Federal Decree-Law No. 41 of 2024 (Art. 87) governing genetic testing on minors.
- Patient is unable to provide voluntary informed consent due to cognitive impairment, and no legally authorized representative is available.
- Patient has undergone allogeneic bone marrow transplantation within the past 12 months (donor DNA may confound germline genetic results).
- Sample is hemolyzed, clotted, or improperly preserved outside cold-chain specifications (2–8°C for whole blood; room temperature for FTA card).
- Pre-test genetic counselling session has not been completed — this is a mandatory prerequisite per DHA genetic testing regulations.
🚨 Emergency Red Flags — Seek Immediate Medical Attention If:
- Sudden onset of severe psychiatric symptoms (suicidal ideation, psychosis, acute agitation) following result disclosure.
- Acute neurological deterioration (rapidly progressive chorea, dysphagia with aspiration risk, falls with head injury).
- Any adverse event related to the blood draw: persistent bleeding, hematoma expansion, signs of infection at phlebotomy site (erythema, warmth, purulent discharge), or vasovagal syncope lasting >2 minutes.
Patient FAQ & Clinical Guidance
Q1: What exactly does the ZDHHC17 gene tell me about my Huntington disease risk or progression?
Snippet: The ZDHHC17 NGS test identifies modifier gene variants that can influence the age at which Huntington disease symptoms first appear and how rapidly they progress, providing personalized prognostic information beyond the standard CAG repeat count alone.
The ZDHHC17 gene encodes HIP14, a palmitoyltransferase enzyme that modifies the huntingtin protein post-translationally. Specific variants in this gene have been shown in peer-reviewed studies to shift HD onset earlier or later by several years, independent of CAG repeat length. This means two individuals with identical CAG repeat sizes may experience vastly different clinical courses depending on their ZDHHC17 status. Our NGS test sequences all coding exons, intron-exon boundaries, and regulatory regions to provide the most complete modifier profile available in the UAE. Results are interpreted by our clinical genomics team and correlated with your neurological evaluation to deliver a holistic risk assessment.
Q2: How do I prepare for the blood draw, and is the home collection service truly reliable?
Snippet: No fasting is required for this genetic test; simply ensure you are well-hydrated, and our DHA-licensed VIP mobile phlebotomy team will arrive at your doorstep with full cold-chain equipment within a 2-hour scheduled window.
Preparation is minimal: maintain normal hydration by drinking water before the appointment, wear loose-fitting sleeves for easy venous access, and have your Emirates ID and insurance card ready for verification. Our home collection service operates daily from 8:00 AM to 11:00 PM across Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. Each phlebotomist carries a DHA-issued professional license, and all samples are immediately placed in ISO-certified cold-chain transport containers (2–8°C) with real-time temperature logging. Samples reach our central laboratory within 4 hours of collection, guaranteeing DNA integrity for NGS analysis. If you opt for an FTA card collection (finger-prick), the process is even simpler and the card is stable at ambient temperature.
Q3: Will my genetic data be kept confidential under UAE law, and can this test affect my insurance coverage?
Snippet: Your genetic data is fully protected under the UAE Personal Data Protection Law (PDPL), stored on encrypted servers with zero third-party sharing, and cannot legally be used to deny insurance coverage under Federal Decree-Law No. 41 of 2024.
Under the UAE PDPL and Federal Decree-Law No. 41 of 2024 (Article 87), all genetic information is classified as sensitive personal data requiring the highest level of protection. Our laboratory employs AES-256 encryption for data at rest, TLS 1.3 for data in transit, and strict role-based access controls. Your sequenced DNA sample is stored under a double-coded anonymization protocol, and only your referring physician and licensed genetic counsellor can link the data back to your identity. Critically, Article 87 explicitly prohibits insurers from using genetic test results to deny coverage, adjust premiums, or impose exclusion clauses. We provide every patient with a Data Privacy Consent Form in both English and Arabic prior to testing, and you retain the right to request complete data deletion at any time.
بموجب قانون حماية البيانات الشخصية الإماراتي والمرسوم بقانون اتحادي رقم 41 لسنة 2024 (المادة 87)، تُصنف جميع البيانات الجينية كبيانات شخصية حساسة تتطلب أعلى مستوى من الحماية. يضمن مختبرنا تشفير جميع البيانات وتخزينها بشكل آمن مع عدم مشاركتها مع أي طرف ثالث، ويُحظر قانوناً على شركات التأمين استخدام نتائج الفحوصات الجينية لحرمانك من التغطية أو رفع أقساط التأمين.
Regulatory Compliance Statement: This diagnostic service is provided in strict accordance with Federal Decree-Law No. 41 of 2024 (Article 87) on Genetic Testing Regulation, the UAE Personal Data Protection Law (PDPL), and the CDS Law 2026 provisions governing genetic testing on minors. Our facility holds DHA License No. 9834453 and ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139). All clinical interpretations are rendered by DHA-licensed physicians. results must be correlated with clinical findings and are not a substitute for specialist neurological evaluation. © 2026. For inquiries, contact our compliance officer via WhatsApp: +971 54 548 8731.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians